View : 95 Download: 0

Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia

Title
Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia
Authors
Lee Y.-P.Yoon S.E.Song Y.Kim S.J.Yoon D.H.Chen T.-Y.Koh Y.I.Kang K.W.Lee H.Wei K.T.K.Lim S.T.Poon M.Irawan C.Zhao W.Do Y.R.Lee M.H.Ng S.C.Lee W.-S.Guo Y.Zhang H.Kang H.-J.Yun H.J.Kim H.J.Lung D.T.C.Kwak J.-Y.Han J.J.Mun Y.-C.Oh S.Y.Shim H.Kwon J.H.Sohn B.S.Park S.K.Jo J.C.Ko Y.H.Jun Z.Kim W.S.
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2021
Journal Title
International Journal of Hematology
ISSN
0925-5710JCR Link
Citation
International Journal of Hematology vol. 114, no. 3, pp. 355 - 362
Keywords
CutaneousIncidenceLymphomaPrognosisSurvivalT-cellTherapeutics
Publisher
Springer Japan
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Cutaneous T-cell lymphomas (CTCLs) are a group of T-cell lymphomas with low incidence. Due to their indolent characteristics, treatment strategies have not yet been established for advanced CTCLs. In this study, relative incidence of CTCLs in Asia was estimated and the therapeutic outcomes presented based on various treatments currently used in clinics for advanced CTCLs. As part of a prospective registry study of peripheral T-cell lymphoma (PTCL) conducted across Asia, including Korea, China, Taiwan, Singapore, Malaysia, and Indonesia, subgroup analysis was performed for patients with CTCLs. Among 486 patients with PTCL, 37 with CTCL (7.6%) were identified between April 2016 and February 2019. Primary cutaneous ALK-negative anaplastic large cell lymphoma (ALCL, 35.1%) was the most common subtype. With a median follow-up period of 32.1 months, median progression-free survival (PFS) was 53.5 months (95% CI 0.0–122.5), and overall survival was not reached. 14 patients (48.2%) underwent subsequent treatment after the first relapse, but the response rate was 20% with a PFS of 2.2 months (95% CI 0.3–4.0). Six patients received autologous stem cell transplantation (auto-SCT). However, auto-SCT did not result in better outcomes. Additional studies are needed on standard care treatment of advanced or refractory and relapsed CTCLs. © 2021, Japanese Society of Hematology.
DOI
10.1007/s12185-021-03179-7
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE